Applied Therapeutics Inc (APLT)

Applied Therapeutics (APLT) Income Statement


Applied Therapeutics Income Statement

Last quarter (Q1 2024), Applied Therapeutics's total revenue was $190.00K, a decrease of -98.22% from the same quarter last year. In Q1, Applied Therapeutics's net income was $-83.94M. See Applied Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ -477.00K$ 9.99M--$ 0.00$ 0.00
Cost of Revenue
Gross Profit
$ -477.00K$ 9.99M----
Operating Expense
$ 74.29M$ 74.53M$ 82.95M$ -105.62M$ 94.47M$ 45.58M
Operating Income
$ -74.77M$ -64.53M$ -82.95M$ -105.62M$ -94.47M$ -45.58M
Net Non Operating Interest Income Expense
$ 1.74M$ 1.37M$ 685.00K$ 555.00K$ 559.00K$ 93.00K
Other Income Expense
$ 120.53M$ -56.60M$ 243.00K$ 521.00K$ -54.00K$ -24.00K
Pretax Income
$ -193.56M$ -119.76M$ -82.51M$ -105.58M$ -93.96M$ -45.51M
Tax Provision
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -223.14M$ -119.76M$ -82.51M$ -211.17M$ -93.96M$ -45.51M
Basic EPS
$ -1.85$ -1.42$ -2.18$ -4.12$ -4.28$ -3.55
Diluted EPS
$ -1.85$ -1.42$ -2.18$ -4.12$ -4.28$ -3.55
Basic Average Shares
$ 405.94M$ 84.24M$ 37.83M$ 25.60M$ 21.97M$ 12.83M
Diluted Average Shares
$ 405.94M$ 84.24M$ 37.83M$ 25.60M$ 21.97M$ 12.83M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 74.29M$ 74.53M$ -82.95M$ -105.62M$ 94.47M$ 45.58M
Net Income From Continuing And Discontinued Operation
$ -193.56M$ -119.76M$ -82.51M$ -105.58M$ -93.96M$ -45.51M
Normalized Income
$ -169.70M$ -94.61M--$ -93.96M$ -45.51M
Interest Expense
$ -193.56M$ -64.53M$ -82.51M$ -105.58M$ -94.47M$ -45.58M
$ -191.47M$ -64.18M$ -78.48M$ -100.89M$ -94.09M$ -45.56M
Currency in USD

Applied Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis